Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anupam Jayaram

Ophthalmic Plastic and Reconstructive Surgery Menlo Park, CA Medical Doctor

NPI 1174803944 CMS profile 234574

1225 Crane St, Suite 200, Menlo Park, CA 94025

Open in the dashboard

General payments

$26,094

124 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anupam Jayaram of Menlo Park, CA is reported in the CMS Open Payments database as having received $26,094 across 124 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Ophthalmic Plastic and Reconstructive Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $608 17
2024 General $436 11
2023 General $186 10
2022 General $495 18
2021 General $574 15
2020 General $14,872 21
2019 General $8,924 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anupam Jayaram
  • Ophthalmic Plastic and Reconstructive Surgery median
  • Middle half of Ophthalmic Plastic and Reconstructive Surgery
  • National median

In program year 2025, general payments to Anupam Jayaram were reported at $608. Among 325 Ophthalmic Plastic and Reconstructive Surgery profiles paid that year, the median was $298 and the middle half received between $132 and $820.

Show as a table
Year Anupam Jayaram Ophthalmic Plastic and Reconstructive Surgery median Middle half National median
2019 $8,924 $182 $73–$467 $163
2020 $14,872 $125 $41–$412 $114
2021 $574 $173 $52–$538 $132
2022 $495 $237 $78–$809 $149
2023 $186 $291 $103–$776 $160
2024 $436 $304 $108–$822 $164
2025 $608 $298 $132–$820 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $23,616 52 payments
  2. AbbVie, Inc. $945 36 payments
  3. Solta Medical, a division of Bausch Health US, LLC $586 11 payments
  4. Merz North America, Inc. $237 2 payments
  5. Aerie Pharmaceuticals, Inc. $163 4 payments
  6. Sun Pharmaceutical Industries Inc. $132 6 payments
  7. Galderma Laboratories, L.P. $122 4 payments
  8. Neuronetics, Inc. $110 1 payment
  9. Alcon Vision LLC $65 3 payments
  10. Bausch & Lomb Americas Inc. $46 2 payments
  11. Other $71 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $20,407 10 payments
  2. Food and Beverage $3,933 105 payments
  3. Travel and Lodging $1,754 9 payments
Products named General payments · program years 2019–2025
  1. BOTOX COSMETIC $16,294 34 payments
  2. BOTOX $1,394 49 payments
  3. Cequa $132 6 payments
  4. rhopressa Glaucoma $117 6 payments
  5. Rhopressa Glaucoma $111 1 payment
  6. Rocklatan Glaucoma $111 1 payment
  7. NEUROSTAR TMS THERAPY $110 1 payment
  8. Xelpros $107 5 payments
  9. rocklatan Glaucoma $106 5 payments
  10. BromSite $70 3 payments
  11. Other $137 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$9,162

Medicare's payments for the services billed

Medicare patients

30

Average age 76

Services billed

161

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 50%
Arthritis 40%
Chronic kidney disease 0%
COPD 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $222
$222 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

124 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmic Plastic and Reconstructive Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record